Our research
Discover pathogenic glycosylation
We aim to decode pathogenic glycosylation patterns associated with neurodegenerative disorders. We use glycomics, glycoproteomics and other methods to analyze alterations in protein glycosylation in brain, cerebrospinal fluid and blood at different stages of Alzheimer´s disease and other forms of dementia and neurodegenerative disorders compared to healthy controls.
Develop and implement glycan biomarkers
We aim to validate glycan- and glycopeptide biomarkers identified via glycomics and glycoproteomics studies described above and develop clinically useful methods for prediction of cognitive decline and for early diagnosis of AD and other dementias. Glycan and glycopeptide levels are correlated with other biomarkers and clinical parameters, including cognition.
Elucidate cellular mechanisms at super-resolution
We use a combination of cutting-edge microscopic techniques for live or fixed cells to elucidate subcellular locations of pathogenic events, such as altered trafficking and sites of protein aggregation. For instance, we study pathogenic events leading to intracellular aggregation of the amyloid β-peptide (Aβ) and tau phosphorylation. We a study how changes in protein glycosylation affect the effects on such pathogenic events. The aim is to identify targets for novel glycan-based treatment strategies.
Elucidate the role of neurogenesis in Alzheimer´s disease
To elucidate the role of neurogenesis at early stages of Alzheimer’s disease (AD) we use AD mouse models in which we have previously shown changes in neurogenesis and neuritogenesis by proteomics studies. We use immunohistochemistry and immunocytochemistry to label neurogenesis markers at different stages of disease development.
PREDEM – a primary care study in Region Stockholm
We are conducting a primary care study within PREDEM – an innovation environment for prevention of dementia. This study evaluates a targeted screening approach using digital cognitive tests and blood-based biomarkers (BBMs) to identify individuals at risk of AD. Participants aged ≥ 65 years and stratified into three risk groups: a) without hypertension or type 2 diabetes, b) with hypertension only, and c) with type 2 diabetes with or without hypertension are recruited from primary care centers in Region Stockholm. A total of 1200 participants (400 per group) will be recruited and followed-up after two years.